The work of C4, the NHMRC Centre for Research Excellence in Cervical Cancer Control is divided into four streams:
Stream 1: Cervical Screening
Stream Leads: Professor Karen Canfell and Associate Professor Marion Saville (co-leads).
The Cervical Screening stream aims to:
- Analyse the outcomes of the Compass trial and the renewed cervical screening program in Australia.
- Produce world first data evaluating primary HPV screening in a national population with extensive HPV vaccination.
- Examine whether self-collection can increase participation rates for cervical screening.
Stream 2: HPV Methods
Stream Leads: Professor Suzanne Garland and Associate Professor Julia Brotherton (co-leads).
The HPV Methods stream aims to:
- Assess how HPV screening and HPV typing results can be best used in the evaluation of screening and vaccination impact.
- Develop methods for predicting underlying disease in the presence of HPV.
Stream 3: HPV Vaccination Strategies
Stream Leads: Associate Professor Julia Brotherton and Professor Suzanne Garland (co-leads).
The HPV Vaccination Strategies stream aims to:
- Assess the impact of the HPV vaccination program on HPV, cervical disease and cervical cancer incidence.
- Research future vaccination strategies to improve coverage, use new vaccines or schedules, and understand the role of HPV immunisation of at-risk groups.
Stream 4: Global Health
Stream Leads: Professor Karen Canfell, Professor Philip Castle, Professor John Kaldor, Professor Suzanne Garland (co-leads).
The Global Health stream aims to:
- Extend research themes and learnings beyond Australia into other developed countries and higher burden settings (Low and Middle Income Countries)
- Evaluate a range of new options for vaccination and screening in China
- Investigate the new HPV POC test with the potential to improve the detection and early treatment of cervical cancer in Papua New Guinea, and to inform cervical screening strategies approaches in other high-burden, low-income countries worldwide.
- Investigate cost-effective cervical cancer control strategies in HIV-positive women
- Investigate the impact of, and economic case for, HPV vaccination to older ages e.g. to age 45 years.
- Build on existing understanding of HPV vaccine hesitancy and how it is spread globally, including between country differences in key concerns.
- Use modelling to predict the global burden of cervical cancer over the next half century.